TAVI Risk Score Calculator

Clinical calculation support · Verify results before clinical use

FRANCE-2 risk-factor review

Review the published early-mortality predictors reported for patients undergoing TAVI. This checklist does not generate an individual mortality probability.

0/9Factors

Patient age is 90 years or older.

Body mass index below 30 kg/m².

Severe symptoms at rest or with minimal activity, consistent with NYHA class IV.

Pulmonary hypertension documented in the clinical assessment.

Critical haemodynamic status as defined by the original study.

Two or more pulmonary-oedema episodes in the preceding 12 months.

Respiratory insufficiency documented in the clinical assessment.

Patient is receiving dialysis.

Planned access is transapical or another non-transfemoral route.

0Selected
Checklist summary
No factors selected
Select the findings that apply. Unknown items are not counted as absent.
Important: The count is a descriptive checklist only, not the validated FRANCE-2 point score and not a percentage estimate of 30-day mortality. Do not use it to make treatment decisions.

Clinical context

The FRANCE-2 early-mortality model was developed from 3,833 consecutive TAVI patients and predicted 30-day or in-hospital mortality. The published model identified nine predictors: age ≥90 years, BMI <30 kg/m², NYHA class IV, pulmonary hypertension, critical haemodynamic state, at least two pulmonary-oedema episodes in the preceding year, respiratory insufficiency, dialysis, and a transapical or other non-transfemoral approach.

The original publication derived a 21-point score. Its discrimination was moderate, with a C-index of 0.67 in the development cohort and 0.59 in the validation cohort. This implementation deliberately does not reproduce the point score because the source coefficients/point weights were not independently verified here.

Predictors represented in this checklist

PredictorCriterion represented
Age ≥90 yearsPatient age is 90 years or older.
BMI <30 kg/m²Body mass index below 30 kg/m².
NYHA class IVSevere symptoms at rest or with minimal activity, consistent with NYHA class IV.
Pulmonary hypertensionPulmonary hypertension documented in the clinical assessment.
Critical haemodynamic stateCritical haemodynamic status as defined by the original study.
≥2 episodes of pulmonary oedema in the previous yearTwo or more pulmonary-oedema episodes in the preceding 12 months.
Respiratory insufficiencyRespiratory insufficiency documented in the clinical assessment.
DialysisPatient is receiving dialysis.
Non-transfemoral accessPlanned access is transapical or another non-transfemoral route.

References

Iung B, Laouénan C, Himbert D, et al.; FRANCE 2 Investigators. Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score. Heart. 2014;100(13):1016–1023. DOI: 10.1136/heartjnl-2013-305314; PMID: 24740804.
Ando T, et al. TAVI or No TAVI: identifying patients unlikely to benefit from transcatheter aortic valve implantation. European Heart Journal. Review summarising FRANCE-2 predictors and discrimination. Publisher page.
Clinical disclaimer: This page is an educational checklist, not a validated risk calculator or substitute for the original score, Heart Team assessment, current guidelines, or clinician judgement. Confirm all variables and definitions against the original publication and local clinical documentation. A selected-factor count must not be interpreted as an absolute risk or as an indication for or against TAVI.